Date: 2015-10-13
Type of information: Series C financing round
Company: Audentes Therapeutics (USA - CA)
Investors: Sofinnova Ventures (USA - CA) Redmile Group (USA - CA) RA Capital Management (USA - MA) funds and accounts advised by T. Rowe Price Associates (USA - MD), Rock Springs Capital Management (USA - MD) Cormorant Asset Management (USA - MA) Cowen Private Investments (USA - NY) Foresite Capital (USA - NY) OrbiMed (USA - NY) 5AM Ventures (USA - CA) Versant Ventures (USA - CA) Deerfield Management Company (USA - NY) Venrock (USA - CA)
Amount: $65 million
Funding type: series C financing round
Planned used: Audentes Therapeutics is developing new treatments for people with serious, rare diseases through the application of AAV gene therapy technology. The company has three products in development, AT001 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT002 for the treatment of Pompe disease, and AT003 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The proceeds from the Series C financing will be primarily used to advance the company’s three lead development programs to key clinical milestones and to establish internal GMP manufacturing capabilities.
Others: * On October 13, 2015, Audentes Therapeutics, a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, announced the closing of an oversubscribed $65 million Series C financing. The financing was co-led by existing investor Sofinnova Ventures and new investor Redmile Group. Additional new investors include RA Capital Management, funds and accounts advised by T. Rowe Price Associates, Inc., Rock Springs Capital Management LP, Cormorant Asset Management LLC, Cowen Private Investments, and Foresite Capital. Existing investors OrbiMed, 5AM Ventures, Versant Ventures, Deerfield Management Company and Venrock also participated.
Therapeutic area: Rare diseases - Genetic diseases
